Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (1)
  • May 2012 (1)
  • December 2011 (1)
  • November 2011 (3)
  • October 2011 (4)
  • September 2011 (4)
  • August 2011 (6)
  • July 2011 (13)
  • June 2011 (8)
  • May 2011 (10)
  • April 2011 (14)
  • March 2011 (6)
  • February 2011 (2)
  • February 2010 (4)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)

    Subscribe in a reader

    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

    NPC Blog

    Nutra Pharma Letter to Shareholders

    Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.

    December 18, 2012Coral Springs, Florida — Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company’s Chief Executive Officer, Rik J Deitsch, had published a Shareholder Letter on the Company’s website.

    “We have been very busy here at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “I wanted to take this opportunity to update our shareholders and the public on the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.

    Click here to read on…

    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Letter to Shareholders", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Pharma Letter to Shareholders digg:Nutra Pharma Letter to Shareholders spurl:Nutra Pharma Letter to Shareholders wists:Nutra Pharma Letter to Shareholders simpy:Nutra Pharma Letter to Shareholders newsvine:Nutra Pharma Letter to Shareholders blinklist:Nutra Pharma Letter to Shareholders furl:Nutra Pharma Letter to Shareholders reddit:Nutra Pharma Letter to Shareholders fark:Nutra Pharma Letter to Shareholders blogmarks:Nutra Pharma Letter to Shareholders Y!:Nutra Pharma Letter to Shareholders smarking:Nutra Pharma Letter to Shareholders magnolia:Nutra Pharma Letter to Shareholders segnalo:Nutra Pharma Letter to Shareholders gifttagging:Nutra Pharma Letter to Shareholders


    No comments yet.

    RSS feed for comments on this post.

    TrackBack URL

    Leave a Comment

    Quick Nav
    Nyloxin // Chronic Pain Relief
    Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


    Recent News
    March 14, 2017
    Nutra Pharma CEO Rik Deitsch Interviewed by

    February 22, 2017
    Global Small Caps Initiates Coverage on Nutra Pharma

    February 15, 2017
    Nutra Pharma and Nyloxin Featured on NBC News-Miami

    Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
    Facebook   Twitter
    Privacy Policy Code of Ethics